Advancements in implant techniques and
rising demand for biological solutions over mechanical solutions are likely to
create opportunities for the market. Technological advancements in
biomaterials, which are utilized in the production of orthobiologics, are
anticipated to support market growth. Such advancements include development of
recombinant biologic agents, modifications in graft designs, stem cell therapy,
and cultured tissue scaffolds. These innovations are likely to provide
benefits, such as smaller incisions, improved biocompatibility, and reduced
procedure time. Reduction in post-operative complications using these
innovative solutions is expected to boost market growth in the years to come.
Furthermore, increasing prevalence of obesity and arthritis, especially in
developed countries is expected to boost market growth. This has, in turn,
increased the demand for minimally invasive surgeries that generally include
bone grafting and growth factor treatments. Orthobiologic therapy is one of the
key components of regenerative medicine that are used to treat musculoskeletal
diseases, including degenerative osteoarthritis. It is one of the important
treatment options for early osteoarthritis (OA) of the knee.
However, strict regulatory framework
regarding approval of orthobiologics and high cost of these products are
anticipated to challenge the market.
Browse Details of Report @ https://www.hexaresearch.com/research-report/orthobiologics-market
Orthobiologics include a wide range of products, such as bone matrix (DBM), allograft, synthetic bone substitutes, bone morphogenetic protein (BMP), stem cell therapy, and viscosupplementation. Viscosupplementation holds a prominent share in the market due to its high adoption in diseases, such as hip degenerative joint disease and osteoarthritis. Benefits, including fewer side effects, pain reduction, better knee movement, and less-invasive nature, are likely to boost the product’s demand. Moreover, increasing popularity of minimally invasive surgeries is anticipated to boost the segment’s growth in the coming years. Orthobiologics are extensively used in applications, such as spinal fusion, trauma repair, and reconstructive surgery. Spinal fusion is a leading application in the market due to increasing use of demineralized bone matrices, bone morphogenetic proteins, and autografts and allografts in spinal fusion surgeries. This could be attributed to its ability to speed up the bone healing process and offer high bone stability, facilitating long-term improvement of spinal disorders. It also offers fast stimulation of cells to enable bone formation and avoids hospital stays and repetitive visits. Key end users of orthobiologics include hospitals and orthopedic clinics. Hospital occupies a larger share in the market than clinics due to increasing use of orthobiological products in various spinal and reconstructive surgeries conducted in hospitals.
North America is one of the leading
regional markets due to presence of key players involved in undertaking new
product development strategies. In addition, availability of better
compensation policies for soft tissue healing and fusion improvement products
is boosting regional market growth.
Asia Pacific is projected to witness
strong growth in the years to come owing to rising healthcare expenditure and
improving economic conditions. Additionally, increasing awareness regarding
availability of these products among physicians is likely to increase their
sales. Frequent product launch and improvement in healthcare infrastructure are
also projected to offer remunerative gains in the years to come.
Some of the key players operating in
the orthobiologics market are DePuy Synthes, Inc.; Medtronic; Stryker
Corporation; Genzyme; and Smith & Nephew plc. Players are increasingly
investing in R&D activities and taking up strategies, such as mergers and
acquisitions, to gain a competitive edge in the market. Moreover, increasing
collaborations between biotechnology and medical device companies for the
development of effective orthobiologics is expected to support market growth.
For instance, BONESUPPORT, a prominent
company in orthobiologics for the management of bone voids, announced that it
has started selling CERAMENT BVF through its own US distributor network.
Similarly, Cesca Therapeutics Inc. announced that its subsidiary named
ThermoGenesis, introduced its PXP System. The system offers fast processing of
autologous bone marrow cells in the point-of-care (POC) setting.
Browse
Related Category Market Reports@ https://www.hexaresearch.com/research-category/healthcare-industry
About Us:
Hexa Research is a market research and
consulting organization, offering industry reports, custom research and
consulting services to a host of key industries across the globe. We offer
comprehensive business intelligence in the form of industry reports which help
our clients obtain clarity about their business environment and enable them to
undertake strategic growth initiatives.
Contact Us:
Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018
United States
Phone: +1-800-489-3075
Email: sales@hexaresearch.com
Website - https://www.hexaresearch.com
No comments:
Post a Comment